Squarepoint
GBIO

Squarepoint’s Generation Bio GBIO Stock Holding History

Squarepoint’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-51,827
Closed -$166K – 4570
2025
Q2 		$166K Buy
51,827
+7,896
+18% +$30.4K ﹤0.01% 4036
2025
Q1 		$178K Buy
43,931
+37,368
+569% +$263K ﹤0.01% 4056
2024
Q4 		$69.6K Buy
+6,563
New +$117K ﹤0.01% 4781
2024
Q1 		– Sell
-11,023
Closed -$182K – 4211
2023
Q4 		$182K Buy
11,023
+5,572
+102% +$97.2K ﹤0.01% 3633
2023
Q3 		$207K Buy
5,451
+467
+9% +$22.1K ﹤0.01% 3392
2023
Q2 		$274K Buy
+4,984
New +$229K ﹤0.01% 3022
2022
Q2 		– Sell
-3,776
Closed -$277K – 3050
2022
Q1 		$277K Buy
+3,776
New +$219K ﹤0.01% 2323
2021
Q3 		– Sell
-2,294
Closed -$617K – 3084
2021
Q2 		$617K Buy
+2,294
New +$686K ﹤0.01% 1988
2021
Q1 		– Sell
-1,378
Closed -$391K – 3284
2020
Q4 		$391K Buy
+1,378
New +$442K ﹤0.01% 2009

Other funds holding GBIO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Squarepoint's GBIO Position: Q3 2025 in Review

Squarepoint sold out of Generation Bio (GBIO) in Q3 2025, closing a stake of 51,827 shares — an estimated $166K sold.

Squarepoint first reported a position in GBIO in Q4 2020 and held it in 9 quarters. The position peaked at $617K in Q2 2021. 41 funds tracked by Wall St. Rank hold GBIO as of Q3 2025.

  • Squarepoint reported no remaining Generation Bio position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 51,827 Generation Bio shares in Q3 2025, an estimated $166K.
  • Squarepoint first reported a position in Generation Bio in Q4 2020 and held it in 9 quarters.
  • Squarepoint's Generation Bio position peaked at $617K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Generation Bio as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.